Sildenafil citrate (Viagra®)

Drugs of Today

Volumn 36, Issue 2-3, 2000, Pages 125-134

  Brock, Gerald ^a  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CYTOCHROME P450 INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; LOOP DIURETIC AGENT; MIBEFRADIL; NITRATE; POTASSIUM SPARING DIURETIC AGENT; RIFAMPICIN; SILDENAFIL;

CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; ERECTILE DYSFUNCTION; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HEADACHE; HUMAN; HYPERTENSION; MALE; NOSE CONGESTION; RASH; SPINAL CORD INJURY; URINARY TRACT INFECTION; VERTIGO; VISUAL DISORDER;

EID: 0034019709     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.2-3.568786     Document Type: Conference Paper

References (32)

1. Eardley, I., Morgan, R., Dinsmore, W., Pearson, J., Wulff, M., Boolel, M. UK-92, 480, A new oral therapy for erectile dysfunction: A double-blind, placebo controlled trial with treatment taken as required. J Urol 1996, 155: Abst 355.
2. Gingell, C.J., Jardin, A., Olsson, A. et al. UK-92,480, a new oral treatment for erectile dysfunction: A double-blind, placebo-controlled, once daily dose response study. Multicentre Study Group. J Urol 1996, 155: Abst 353.
3. Ballard, S.A., Burslem, F., Gingell, C. et al. In vitro profile of UK-92,480, an inhibitor of cyclic GMP-specific phosphodiesterase 5 for the treatment of male erectile dysfunction. J Urol 1996, 155: 676A.
4. Viagra® (package insert). NY, Pfizer, Inc., New York 1998.
5. Terrett, N.K., Bell, A.S., Brown, D., Ellis, P. Sildenafil (Viagra™), A potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 1996, 6: 1819-24.
6. Boolell, M., Gepi-Attee, S., Gingell, J.C., Allen, M.J. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996, 78: 257-61.
7. Langtry, H.D., Markham, A. Sildenafil: A review of its use in erectile dysfunction. Drugs 1999, 57: 967-89.
8. Ballard, S.A., Gingell, C.J., Tang, K. et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998, 159: 2164-7.
9. Boolell, M., Allen, M.J., Ballard, S.A. et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int J Impot Res 1996, 8: 47-52.
10. Rance, D.J., Atkinson, F.M., James, G.C. et al. The pharmacokinetics of sildenafil after single intravenous and oral doses to mouse, rat and dog. Br J Clin Pharmacol 1996, 42: 267-8.
11. Rosen, R.C., Riley, A., Wagner, G., Osterloh, I.H., Kirkpatrick, J., Mishra, A. The International Index of Erectile Function (UEF): A multi-dimensional scale for assessment of erectile dysfunction. Urology 1997, 49: 822-30.
12. Jeremy, J.Y., Ballard, S.A., Naylor, A.M., Miller, M.A.W., Angelini, G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997, 79: 958-63.
13. Rendell, M.S., Rajfer, J., Wicker, P.A., Smith, M.D. Oral sildenafil for the treatment of erectile dysfunction in men with diabetes. JAMA 1999, 281: 421-6.
14. Goldstein, I., Lue, T.F., Padma-Nathan, H., Rosen, R.C., Steers, W.D., Wicker, P.A. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998, 338: 1397-404.
15. Montorsi, F., McDermott, T.E.D., Morgan, R. et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999, 53: 1011-8.
16. Morales, A., Heathcote, P. Oral sildenafil (Viagra™) in the treatment of erectile dysfunction: Efficacy of 50-mg, 100-mg, and 200-mg doses, Int J Impot Res 1998, 10(Suppl 3): Abst 300.
17. Olsson, A.M., Abramsson, L., Grenabo, L. et al. Peroral treatment of erectile dysfunction with Sildenafil (Viagra™) (UK-92, 480): A double-blind, placebo-controlled, international multicentre study. Scand J Urol Nephrol 1996, 30:9.
18. Derry, F.A., Dinsmore, W,W., Fraser, M. et al. Efficacy and safety or oral sildenafil (Viagra™) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998, 51: 1629-31.
19. Lue, T.F. A study of sildenafil (Viagra™), a new oral agent for the treatment of male erectile dysfunction. Sildenafil Study Group. J Urol 1997, 157 (Suppl.): 181.
20. Cusin, B., Emrich, H.M., Meuleman, E.J.H. et al. Sildenafil (Viagra™): A 6-month, double-blind, placebo-controlled, flexible dose-escalation study in patients with erectile dysfunction. 2nd Meet Eur Soc Impot Res (Oct 1-4), Madrid) 1997, Abst 159.
21. Padma-Nathan, N., Steers, W.D., Wicker, P.A. et al. Efficacy and safety or oral sildenafil in the treatment of erectile dysfunction: A double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998, 52: 375-80.
22. Hodges, M., Hargreaves, C.K., Smith, M.D. et al. Sildenafil (Viagra™), an oral treatment for erectile dysfunction (ED): A 12 week, double-blind, placebo-controlled study, Int J Impot Res 1997, 9(Suppl. 1): S46.
23. Holmgren, E., Giuliano, F., Hultling, C. et al. Sildenafil (Viagra™) in the treatment of erectile dysfunction (ED) caused by spinal cord injury (SCI): A double-blind, placebo-controlled, flexible-dose, two-way crossover study. Neurology 1998, 50(Suppl. 4): A127.
24. Rendell, M.S., Moreno, F. A double-blind, placebo-controlled, flexible dose-escalation study assessing the efficacy and safety of sildenafil (Viagra™) in men with erectile dysfunction and diabetes. Diabetes 1998, 47(Suppl. 1): Abst 0033.
25. Montorsi, F., Morgan, R.J., Olsson, A.M. et al. Sildenafil (Viagra™): A 3-month, double-blind, placebo-controlled, fixed-dose study in patients with erectile dysfunction. Eur Urol 1998, 33(Suppl. 1): 40.
26. Price, D.E. Sildenafil in the treatment of erectile dysfunction in diabetic men. Sildenafil Study Group. Diabetic Med 1998, 15(Suppl. 2): S6.
27. Bailey, M., Hodges, M., Osterloh, I. et al. Sildenafil (Viagra™), a new oral treatment for erectile dysfunction: Results of an 8-week double-blind, placebo-controlled parallel group study. Br J Urol 1997, Suppl. 4: 19.
28. Dinsmore, W.W., Gingell, C.J., Jardin, A. et al. Sildenafil (Viagra™), a new oral treatment for erectile dysfunction (ED): A double blind, placebo controlled, parallel group, once daily dose response study, Int J Impot Res 1996, 8: 147.
29. Feldman, R. Sildenafil in the treatment of erectile dysfunction: Efficacy in patients taking concomitant antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 1998, 11(4, Part 2): 10A.
30. Wagner, G., Maytom, M., Smith, M.D. Analysis of the efficacy of sildenafil (Viagra™) in the treatment of male erectile dysfunction in the elderly. J Urol 1998, 159 (Suppl.): 239.
31. Hargreave, T.B. Efficacy of sildenafil in the treatment of erectile dysfunction in patients with depression. 21st CINP Cong (July 12-16, Glasgow) 1998, Abst PM05021.
32. ACC/AHA Expert Consensus Document on the Use of Sildenafil in Patients with Cardiovascular Disease. J Am Coll Cardiol 1999, 33: 273-83.